Effect And Safety Of Paclitaxel-Eluting Balloon Therapy In The Treatment Of Stent Restenosis-A Meta-Analysis Of Randomized Clinical Trials

BackgroundNowadays, percutaneous coronary intervention has become an important treatment for coronary disease. Bare metal stent and drug-eluting stent make prognosis better than before, but also bring new problem——in-stent restenosis (ISR). DEB may be an effect way to reduce ISR Paclitaxel can inhibit neointimal proliferation, PEB has potentialin in the treatment of stent restenosis.ObjectiveTo estimate the efficacy of paclitaxel-eluting balloon (PEB) in coronary artery in-stent restenosis.MethodsWe conducted the meta-analysis by searching PubMed, CNKI, Embase, Cochrone and other sources, abstracted data in clinical trials which fits our inclusive criteria. RevMan version 5.0 was considered as the tool to analyze data.Results6 randomized controlled clinic trials with 801 patients were included. From data of 6 months, PEB compared with common balloon (CB) was associated with a significantly lower rate for minimal lumen diameter (OR=0.54; 95 %CI,0.45 to 0.64; P<0.01), late luminal loss (OR=-0.48; 95%CI,-0.60 to -0.36; P<0.01), binary restenosis (OR=0.13; 95%CI, 0.25-0.40; P<0.01), target lesion revascularization (TLR) (OR=0.15; 95% CI,0.06 to 0.36; P<0.01), total mortality(OR=0.34; 95%CI,0.13 to 0.89; P=0.03) and major adverse cardiovascular events (MACE) (OR=0.14; 95% CI,0.08 to 0.23; P<0.01). Additionally, PEB is superior on minimal diameter to CB.ConclusionsPEB had an obvious advantage than CB in coronary artery in-stent restenosis, as a new choice, it shows great potential.